Research Article
Role of SH Levels and Markers of Immune Response in the Stroke

Maria Musumeci, 1 Stefano Sotgiu, 2 Silvia Persichilli, 3 Giannina Arru, 2 Silvia Angeletti, 1 Maria Laura Fois, 2 Angelo Minucci, 3 and Salvatore Musumeci 4,5

1 Center for Integrated Research, Department of Laboratory Medicine and Microbiology, Campus Bio-Medico, University of Rome, Italy
2 Institute of Clinical Neurology, University of Sassari, Italy
3 Clinical Biochemistry Laboratory of Catholic University, Rome, Italy
4 Department of Chemical Sciences, University of Catania, Viale Andrea Doria no. 6, 95125 Catania, Italy
5 Institute of Biomolecular Chemistry, CNR, Catania, Italy

Correspondence should be addressed to Salvatore Musumeci; smusumeci@tiscali.net.it

Received 15 June 2013; Revised 27 July 2013; Accepted 28 July 2013

Academic Editor: Donald H. Chace

Copyright © 2013 Maria Musumeci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Sulphydryl groups (SH) are considered a key factor in redox sensitive reaction of plasma, and their modification could be considered an expression of abnormal generation of oxygen free radicals. Methods. Fifty consecutive patients with acute brain stroke were enclosed in this study. The plasma concentrations of SH groups were correlated to cytokines (IL-1β, IL-6, IL-8, TNF-α), plasma chitotriosidase (Chit), metalloprotease (MMP2–9), intercellular adhesion molecule-1 (ICAM-1).

Results. The results demonstrated a significant reduction of SH groups within 24 hours from the onset of an acute ischemic stroke, a reduction of plasma IL-1β, IL-6, and IL-8, and an increase of Chit and TNF-α in relation to the stroke severity.

Conclusion. The observation of an intense microenvironment activation that follows the stroke and the correlation between SH levels and markers of immune response suggest that, especially in stroke, is necessary to maintain the redox function to prevent the brain damage. The reduced SH levels represent an attempt to neutralize the abnormal generation of free radicals. Since the reperfusion of brain after ischemic event represents a severe oxidative stress, which must be corrected by regeneration of redox sensitive function, pharmacological intervention could be beneficial in this setting.

1. Introduction
Thiols contain functional SH groups within conserved cysteinyl residue, and thiol-containing proteins are now recognised as key players in redox sensitive reactions of plasma [1]. Their redox sensing abilities are thought to occur by electron flow through the sulfhydryl side chain. The majority of thiols present in cellular proteins are within a highly reducing environment and therefore protected, or buffered, against oxidation [2, 3]. Only protein as albumin with accessible thiol groups and high oxidation potentials are likely to be involved in redox mechanisms [4].

Several evidences demonstrate that such thiol-containing proteins are sensitive to thiol modification when exposed to changes in redox state of different tissues [5].

Plasma is the principal source of reduced thiols: their concentration is about 500 umol/L, they have a high molecular mass, and they are chiefly attributable to albumin [6]. In fact, antioxidant functions of albumin are linked to its ability to bind transition metal ions and bilirubin, and to the radical scavenging properties of its thiol groups [7]. Albumin’s redox active thiol groups are predominantly in the reduced state. In fact, albumin thiol groups can play an important role in extracellular redox balance and subsequent signalling pathways [8]. In the brain, the redox reaction is maintained by ascorbic acid, which is introduced by meals, and it is maintained in the redox status inside the brain, where it protects the cerebral structures from the oxidation [9].

Stroke is a frequent neurological accident in old age and its prevalence in Western countries is high [10]. After an acute brain event, the early glial and endothelial cells are induced to produce transcription of tumour necrosis factor (TNF-α) and interleukin IL-6, which is followed by
a cascade of modulator inflammatory pathways [11]. Local
endothelia is transformed into a prothrombotic state allowing
peripheral mono- and polymorphonuclear cytotoxic cells
to be chemotactically into the lesion site [12, 13]. With a
few exceptions [14], a relationship between the extent of
the brain damage and the early increase of TNF-α and IL-
6 plasma levels has generally been reported in stroke [12-
14]. Though the topic remains controversial, this process
induces an abnormal generation of oxygen free radicals by
microenvironment cells. Moreover, infiltrated macrophages
contribute further to brain damage through the synthesis
of pro- and anti-inflammatory cytokines, including TNF- 
α and IL-10 [15]. Relationships between the extent of brain
damage and the plasma level of TNF-α, IL-6, and, recently,
chitotriosidase (Chit), a marker of macrophage activation,
are reported, though usually in strict relation to pre-existing
and concomitant infectious inflammatory diseases [16]. Our
group demonstrated that this response is generated also in
absence of infection or other mechanism of macrophage
activation [17], limiting this phenomenon to the ischemic
event. In these studies, plasma chitotriosidase and TNF-α
related to the extent of stroke severity and to CT lesion
volume, and the levels of these two markers to date could be
considered the more sensible parameters to follow the stroke
event.

The aim of this study is to evaluate and try to correlate
the plasma concentrations of SH groups to brain damage
volume, to serum cytokines (IL-1b, IL-6, IL-8, TNF-α),
plasma chitotriosidase (Chit), metallocprotease (MMP2–9),
intercellular adhesion molecule-1 (ICAM-1), and to thioles
(cysteine, cysteinylglycine, homocysteine, and glutathione),
in 50 consecutive patients with acute brain ischemia without
concomitant symptoms or signs of inflammatory infectious
diseases. The evaluation of these possible mediators of stroke
could permit to better characterize the redox reaction in the
pathogenesis of stroke damage.

2. Material and Methods

2.1. Patients. Fifty consecutive Caucasian patients with an
acute ischemic stroke, 30 males and 20 females, mean age
64 (range 40–82), were enrolled for this study at Institute of
Neurology, University of Sassari, Italy. Blood samples were
drawn within 24 hours after stroke onset and before pharma-
cologic intervention. Samples were centrifuged and stored at
−80°C until assayed. Exclusion criteria were the clinical evi-
dence of infectious, inflammatory, and autoimmune diseases,
malignancy, severe cardiac or renal or hepatic diseases, recent
transient ischemic attack or previous ischemic-hemorrhagic
strokes, atheromatous diseases, arteriosclerotic heart disease,
hypertension, and pulmonary diseases, anticoagulant or
acetylsalicylic acid therapies. An informed consent to the
study was obtained from all patients or their relatives, and
the protocol of study was approved by Ethical Committee of
Sassari University.

All patients underwent repeated neurological examina-
tions, electrocardiography and ultrasound tomography of
carotid and vertebral arteries. Stroke severity was evaluated
and scored by administering the National Institutes of Health
Stroke Scale (NIHSS) on admission (0–42). NIHSS provides
optimal discrimination of 30-day mortality risk, more than
75% for patients with a score of at least 40. The NIHSS is a
tool used by healthcare providers to objectively quantify the
impairment caused by a stroke. The NIHSS is composed of 11
items, each of which scores a specific ability between 0 and 4.
For each item, a score of 0 typically indicates normal function
in that specific ability, while a higher score is indicative of
some level of impairment. The individual scores from each
item are summed in order to calculate a patient’s total NIHSS
score. The maximum possible score is 42, with the minimum
score being a 0 (Table 1).

<table>
<thead>
<tr>
<th>Score</th>
<th>Stroke severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No stroke symptoms</td>
</tr>
<tr>
<td>1–4</td>
<td>Minor stroke</td>
</tr>
<tr>
<td>5–15</td>
<td>Moderate stroke</td>
</tr>
<tr>
<td>16–20</td>
<td>Moderate to severe stroke</td>
</tr>
<tr>
<td>21–42</td>
<td>Severe stroke</td>
</tr>
</tbody>
</table>

Brain CT was routinely performed on patient admission
and at 7 days by means of a spiral-CT HISPEED/LX/I (Gen-
eral Electric, USA). Each scan was 120 KV, 160 mA, 5 mm
thickness, and 2 sec acquisition time. To avoid imprecise
estimations of the lesion volume, due to the different three-
dimensional conformation of the lesion, we used an accurate
technique for calculating the volume of ischemic brain lesion
according with the Cavalieri’s principle, as described [14].
A control group represented by 20 healthy subjects, mean
age 55 (range 35–70), not suffering of cardiovascular disease,
atheromatous diseases, arteriosclerotic heart disease, hyper-
tension, pulmonary diseases, and carotid atherosclerosis, was
included in this study.

2.2. Cytokines. Enzyme-linked immunosorbent assay
(ELISA) tests for human IL-1b, IL-6, and IL-8 and human
TNF-α (Euroclone, Switzerland) were performed at the
Institute of Neurology, University of Sassari, Italy, according
to indications and suggestions of the manufacturer.
VCAM-1 (vascular cell adhesion molecule), ICAM-1
(intercellular adhesion molecule 1), and BDNF (brain-
derived neurotrophic factor) were measured by enzyme-
linked immunosorbent assay (ELISA). Values were expressed
as pg/mL while VCAM-1 was expressed as ng/mL. The
 intra-assay imprecision was <5%, whereas the interassay
imprecision was <8%. MMP2–9 was measured by the
zymogram method. The gelatinolytic activity is given in
arbitrary units (units/ug protein).

2.3. Thioles. Plasma thioles (cysteine, cysteinylglycine,
homocysteine, glutathione) were measured in HPLC and
expressed in μmol/L at the Clinical Biochemistry Laboratory
of Catholic University, Rome, Italy. Inter-assay coefficient
of variation was 3.6%, calculated by measuring 15 replicates
of a serum sample in the same day. Plasma homocysteine >
15 μmol/L was considered elevated.
Table 2: Clinical and laboratory parameters of 50 patients with brain stroke divided in function of NIHSS score \( \leq 30 \) and \( >30 \).

<table>
<thead>
<tr>
<th></th>
<th>Age (yrs)</th>
<th>VCAM</th>
<th>BDNF</th>
<th>ICAM</th>
<th>MMP2–9</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(A) NIHSS ( \leq 30 )</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( n, 30 )</td>
<td>( M, 20, F, 10 )</td>
<td>67.3 ± 13.0</td>
<td>519 ± 205</td>
<td>43.23 (13.94–337.4)</td>
<td>248.6 ± 86.6</td>
</tr>
<tr>
<td><strong>(B) NIHSS &gt;30</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( n, 20 )</td>
<td>( M, I, F, 9 )</td>
<td>70.3 ± 7.98</td>
<td>683.2 ± 404.0</td>
<td>121.8 (20–1303.9)</td>
<td>360.35 ± 179.71</td>
</tr>
<tr>
<td>A versus B</td>
<td>( P = 0.36 )</td>
<td>( P = 0.064 )</td>
<td>( P = 0.0001 )</td>
<td>( P = 0.005 )</td>
<td>( P = 0.0006 )</td>
</tr>
<tr>
<td><strong>Control groups</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>15.96 ± 4.024</td>
<td>14.24 ± 6.88</td>
<td>201.2 ± 55.0</td>
<td></td>
</tr>
</tbody>
</table>

VCAM: Cytokine-induced cell adhesion molecule (ng/mL); BDNF: Brain-derived neurotrophic factor (pg/mL); ICAM: intercellular adhesion molecules (pg/mL); MMP2–9: matrix metalloprotease 2–9 (units/ug protein).

Table 3: Cytokines (pg/mL), TNF-\( \alpha \), TC volume, Chit (nmol/mL/h) and SH groups (mmol/L) in 50 patients with brain stroke divided in function of NIHSS score \( \leq 30 \) and \( >30 \).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>IL-1( \beta )</th>
<th>IL-6</th>
<th>IL-8</th>
<th>TNF-( \alpha )</th>
<th>TC mm3</th>
<th>Chit</th>
<th>SH groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(A) NIHSS ( \leq 30 )</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( n, 30 )</td>
<td>( M, 20, F, 10 )</td>
<td>212.42 (4.1–1096)</td>
<td>12.23 ± 4.53</td>
<td>74.64 ± 16.47</td>
<td>52.74 ± 26.86</td>
<td>617 (355–5998)</td>
<td>21.90 ± 15.62</td>
</tr>
<tr>
<td><strong>(B) NIHSS &gt;30</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( n, 20 )</td>
<td>( M, I, F, 9 )</td>
<td>166.5 (0.2–975.08)</td>
<td>9.55 ± 5.71</td>
<td>60.32 ± 16.36</td>
<td>225.32 ± 163.60</td>
<td>661I (185–20836)</td>
<td>50.35 ± 35.36</td>
</tr>
<tr>
<td>A versus B</td>
<td>( P = 0.99 )</td>
<td>( P = 0.071 )</td>
<td>( P = 0.004 )</td>
<td>( P = 0.0001 )</td>
<td>( P = 0.0001 )</td>
<td>( P = 0.0003 )</td>
<td>( P = 0.030 )</td>
</tr>
<tr>
<td><strong>Control groups</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.0–5.6</td>
<td>1.9–17.4</td>
<td>0.0–13.3</td>
<td>—</td>
<td>0.0–25</td>
<td>578.6 ± 63.6</td>
</tr>
</tbody>
</table>

2.4. Chit Activity. Chit activity was measured in plasma according to the method reported in Sotgiu et al. [17], at Department of Pediatrics, University of Catania, Italy. Chit activity was measured as nanomoles of substrate (4-methylumbelliferyl-beta-D-N,N,N-triacetylchitotriose, Sigma Chemical Co., USA). Briefly, Chit activity was measured incubating 5 \( \mu \)L of undiluted plasma with 100 \( \mu \)L of a solution containing 22 mMol/L of the fluorogenic substrate 4-methylumbelliferyl-beta-D-N,N,N-triacetylchitotriose (Sigma Chemical Co.) in 0.5 M citrate phosphate buffer pH 5.2, for 15 min at 37°C. The reaction was stopped by using 2 mL of 0.5 mol/L Na\(_2\)CO\(_3\)/NaHCO\(_3\) buffer, pH 10.7. The fluorescence of formed 4-methylumbelliferone was read on a Hitachi 2500 fluorometer, at 365 nm excitation and 450 nm emission. Chit activity was expressed as nanomoles of substrate hydrolyzed per milliliter per hour (nmol/mL per h). Patients with plasma Chit activity below 2.5 nmol/mL per h were considered as Chit deficient.

2.5. Dosage of SH. SH groups were evaluated according to Ellman reaction [18] at the Clinical Biochemistry Laboratory of Catholic University, Rome, Italy, performing the spectrophotometer measurements on an automated chemistry analyser (OLYMPUS 400). The assay is based on the reaction of the SH groups with 5,5′-dithiobis-2-nitrobenzoic acid (DTNB, 2.5 mM) in Tris-\( \text{HCl} \) 0.25 M and EDTA 20 mM (pH 8.2) that develops a yellow-coloured compound, which absorbs at 405 nm. The calibration was obtained by using GSH 1000 \( \mu \)M solution as standard. Intra-assay imprecision was <5%, calculated by measuring the same sample in ten different days. The method is linear up to 10 mM/L, and the sensitivity is 10 mM/L. A control group was selected among healthy individuals who underwent for health balance and resulted in good conditions at the clinical examination.

2.6. Statistical Analysis. Clinical data and inflammatory biomarkers were expressed as median and range and/or mean ± SD where possible. Differences between groups were evaluated through the Mann-Whitney Rank Sum Test. Correlations between inflammatory markers and clinical variables were assessed by using the Spearman Rank Order Correlation coefficient (\( r \)), and the \( P \) value was considered significant when \(<0.05\).

3. Results

3.1. Patients and Outcome. The median NIHSS score was 30 (range 0–42). The intrinsic property of the NIHSS scale (Table I) allowed us stratifying patients in two groups, with better (NIHSS score \( \leq 30 \); 30 patients) and worse outcome (NIHSS score of at least >30; 20 patients). The clinical parameters in the two groups are reported in Table 2. A significant difference was found for VCAM and BDNF, ICAM, and MMP2–9 between the two groups. The VCAM, BDNF, and ICAM values were higher than in healthy controls (Table 2).

3.2. Cytokines, Chitotriosidase, SH Groups, and Thioles. The SH concentration was significantly lower (104.5 ± 67.6 mmol/L) in stroke patients compared to healthy controls (578.6 ± 63.6 mmol/L) (\( P = 0.0001 \)) and significantly lower in the subgroup with worse outcome (\( P = 0.030 \)) (see Table 3).
4. Discussion

Cytokines as IL-6 and IL-8 were higher in patients with NIHSS score <30 (P = 0.071 and P = 0.004, resp.), but the IL-1b was not significantly higher in the same patients. TNF-\(\alpha\) and chitotriosidase were higher in patients with NIHSS score >30 (P = 0.0001 and P = 0.0003 resp.) compared to that with NIHSS score <30 (see Table 3). The median lesion volume was 987 mm\(^3\), significantly larger (P < 0.05) in patients with worse outcome (median 6611 mm\(^3\); range 185–20836) as compared to those with better outcome (median 617, range 355–5998). A significant correlation was found between TNF-\(\alpha\) and Chit (P < 0.05) (see Figure 1).

The thioles were all in the normal range for age, and the slight differences between the two groups NIHSS ≤30 or >30 were not significant except glutathione that was lower in all patients (see Table 4). The correlation between homocysteine and SH was not significant (P = 0.84). A direct positive correlation was found between lesion volume and NIHSS score (r = 0.59, P = 0.01) and negative with SH groups (r = −0.60, P = 0.0001). Significant correlation was found between SH and all the other considered parameters with exception of TNF-\(\alpha\) and ICAM (see Table 5).

Significant correlations were found between homocysteine and glutathione (P < 0.0001) and between SH and glutathione (P = 0.04) (see Figures 2 and 3).

There is a strict relation among the extension of tissue injury in cerebral ischemia and generation of oxygen free radicals [19], alteration of vascular reactivity with migration of peripheral leukocyte, and increase in cytokine release [12–14, 20–22]. In our study, we found a significant reduction of SH groups within 24 hours from the onset of an acute ischemic stroke, an increase of plasma TNF-\(\alpha\) and Chit, and a reduction of IL-6 and IL-8 in relation to the stroke severity. Moreover, IL-6 and IL-8 directly correlate with SH groups consumption, while Chit and SH correlate negatively, especially in patients with worse outcome (see Table 5). Several studies have demonstrated that the level of IL-6 directly relates to both fever and severity of stroke [16–19, 23], which in turn is directly related to the strength of the acute phase. This demonstrates that the innate reaction of stroke is probably due exclusively to the macrophage activation, secondary to the ischemic event.

In this study, plasma Chit and TNF-\(\alpha\) correlated to the extent of the stroke severity, and CT lesion volume and the level of these two marker to date could be considered the more sensibles parameters in the followup of the stroke event, as well as IL-6 is considered a marker of the acute event [24].

There are several links between macrophage activation and stroke and infiltrated macrophages, which may contribute to brain damage through a group of potentially neurotoxic factors such as proinflammatory cytokines, free radicals, glutamate, and metalloproteases [25]. The modification of SH groups in the poststroke period may be considered the consequence of free radical generation. The reduced SH levels may represent a tentative to neutralize the abnormal generation of free radicals.

However, on this topic many questions remain to be answered. For example, why chemoattracted or perhaps resident macrophages such as microglia do activate their gene to produce Chit and other cytokines, showing a direct influence on the tissue damage or they simply reflect an epiphenomenon of a pre-existing situation? We cannot argue for any such hypotheses yet. Our results indicate that Chit activity possibly represents the hallmark of an innate macrophage response, and this activation correlates with the severity of stroke [17]. This parameter could be a novel marker of stroke in addition with other cytokines (IL-6 and IL-8) [14], even if the cytokine upregulation follows as a fall mechanism not sufficiently regulated, which worse often the clinical course of neurological event.
Table 4: Thioles (μmol/L) in 50 patients with brain stroke divided in function of NIHSS score ≤30 and >30.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Cysteine</th>
<th>Cysteinylglycine</th>
<th>Homocysteine</th>
<th>Glutathione</th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) NIHSS ≤ 30 n = 30 (M. 20, F. 10)</td>
<td>196.58 ± 97.65</td>
<td>28.16 ± 19.20</td>
<td>7.93 ± 3.84</td>
<td>1.81 ± 1.81</td>
</tr>
<tr>
<td>(B) NIHSS &gt; 30 n = 20 (M. 11, F. 9)</td>
<td>206.72 ± 104.7</td>
<td>26.30 ± 16.79</td>
<td>9.22 ± 7.86</td>
<td>1.35 ± 1.18</td>
</tr>
<tr>
<td>A versus B</td>
<td>P = 0.72</td>
<td>P = 0.72</td>
<td>P = 0.44</td>
<td>P = 0.32</td>
</tr>
<tr>
<td>Controls groups</td>
<td>193 ± 39.8</td>
<td>24.6 ± 6.2</td>
<td>9.3 ± 3.7</td>
<td>3.05 ± 2.0</td>
</tr>
</tbody>
</table>

Table 5: Spearman rank order correlation of 50 patients with brain stroke.

<table>
<thead>
<tr>
<th>All patients</th>
<th>Age</th>
<th>mm3</th>
<th>NIHSS</th>
<th>SH</th>
<th>IL-1b</th>
<th>IL-6</th>
<th>IL-8</th>
<th>TNF-α</th>
<th>Chit</th>
<th>MMP2–9</th>
<th>ICAM</th>
<th>VCAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>r</td>
<td>no</td>
<td>no</td>
<td>0.219</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>P</td>
<td>0.0125</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mm3</td>
<td>r</td>
<td>0</td>
<td>-0.60</td>
<td>0.59</td>
<td>0.01</td>
<td>0.0001</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>P</td>
<td>0.0001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIHSS</td>
<td>r</td>
<td>0</td>
<td>No</td>
<td>-0.415</td>
<td>-0.351</td>
<td>0.816</td>
<td>0.435</td>
<td>0.488</td>
<td>0.497</td>
<td>0.363</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>0.0029</td>
<td>0.0126</td>
<td>0.000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SH</td>
<td>r</td>
<td>0</td>
<td>No</td>
<td>0.374</td>
<td>0.331</td>
<td>No</td>
<td>-0.296</td>
<td>-0.469</td>
<td>No</td>
<td>0.002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>0.015</td>
<td>0.016</td>
<td>0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-1b</td>
<td>r</td>
<td>0</td>
<td>No</td>
<td>0.337</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>P</td>
<td>0.0171</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>r</td>
<td>0</td>
<td>No</td>
<td>-0.296</td>
<td>-0.333</td>
<td>-0.395</td>
<td>-0.507</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>0.0371</td>
<td>0.0182</td>
<td>0.0047</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-8</td>
<td>r</td>
<td>0</td>
<td>No</td>
<td>-0.355</td>
<td>No</td>
<td>-0.306</td>
<td>No</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>0.0117</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-α</td>
<td>r</td>
<td>0</td>
<td>No</td>
<td>0.479</td>
<td>0.371</td>
<td>0.470</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>0.000</td>
<td>0.0082</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chit</td>
<td>r</td>
<td>0</td>
<td>No</td>
<td></td>
<td>0.535</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMP2–9</td>
<td>r</td>
<td>0</td>
<td>No</td>
<td></td>
<td>0.372</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0080</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICAM</td>
<td>r</td>
<td>0</td>
<td>No</td>
<td></td>
<td>0.317</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0253</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VCAM</td>
<td>r</td>
<td>0</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Another point to consider should be the observation that the patients with stroke could be smokers, alcohol users, or affected by pathologies that reduce the redox status [26, 27] and determine an increase of homocysteinemia. One of the potential injurious effects of hyperhomocysteinemia in the stroke is the free radical generation [28].

In our study, the homocysteine level was found normal, thus indicating that the redox status precedent the acute stroke [29] was normal. The observation of a microenvironment activation, which follows the stroke and the correlation between SH levels and markers of immune response confirms other similar studies [20, 21], but suggests that in stroke is necessary to maintain the redox function to prevent and in particular to contain the brain damage determined by the ischemic event.

Since oxidative stress plays an important role in acute ischemic stroke pathogenesis, free radical formation, and subsequent oxidative damage may be a determinant factor in stroke severity. In fact serum levels of nitric oxide (NO), malondialdehyde (MDA), and glutathione (GSH) were measured within the first 48 h of stroke [30] and correlated with the clinical outcomes. These results suggest deleterious effects of oxidative stress on clinical outcome in acute ischemic stroke and the variation of GSH levels may be an adaptive mechanism during this period.

Since the reperfusion of brain after ischemic event represents a severe oxidative stress that must be corrected by regeneration of redox function [31], a pharmacological intervention could be beneficial in this setting.

Conflict of Interests
Authors declare no conflict of interests in the research.

Acknowledgment
The authors thank Mr. Giuseppe Rapicavoli, Department of Pediatrics, University of Catania for, his skillful technical assistance in laboratory work.

References


